Head, Pediatric Gastroenterology
Department of Pediatrics
Hadassah University Hospital
Ein-Karem, Jerusalem
02- 5844922/068-573572(Tel)
02- 5844697 (Fax)
E-mail: michaelwil@hadassah.org.il
Date of Birth: 10 December 1960, London, England
Immigration: August 1985
Nationality: British, Israeli
Marital Status: Married, 5 children
Military Service: 1990-92
Medical Education
1985 MBBS, Royal Free Hospital School of Medicine, University of London, England
Pediatric Residency
1986-1988 Shaare Zedek Hospital, Hebrew University, Jerusalem, Israel
1989 - Pediatric Hepatology, King's College Hospital, London,England. (Prof. A. Mowat, Supervisor)
1990-1992 Shaare Zedek Hospital, Hebrew University, Jerusalem, Israel. Chief Resident 1991-1992 (Prof. S. Freier, Supervisor)
1992 - Certification (Israel) Pediatrics
pediatric Gastroenterology fellowship
1992-1993 Clinical Fellow, Division of Gastroenterology, The Hospital for Sick Children, Toronto, Canada. (Dr. P. Sherman, Program Director)
1993-1995 Research Fellow, Divisions of Gastroenterology & Cell Biology, The Hospital for Sick Children, Toronto, Canada, (Dr. C. Bear, Dr. P. Durie. Co-supervisors)
1996 - Certification (Israel) Pediatric Gastroenterology
Staff Position
1995-2003 Gastroenterology Unit, Dept. of Pediatrics, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel.
Director, Electrophysiology Laboratory, Shaare Zedek Medical Center.
Head, Pediatric Gastroenterology Unit and Director, Electrophysiology Laboratory, Hadassah Medical Organization, Jerusalem, Israel
2006 - (Accreditation for Sub-specialization until 2011)
Hebrew University Appointments
1995 – 2002 Tutor, Hebrew University, Jerusalem
1/10/2003 - Senior Lecturer in Pediatrics, Hebrew University, Jerusalem
Additional Tasks
Referee on behalf of The Israeli Ministry of Health for validation of the Pediastric Gastroentrology Units at Schneiders Children Hospital (Chairman) Soroka Medical Center and Kaplan Hospital
Other Activities
Ad Hoc Reviewer (last 5 years) for Gut, Chest, Journal of Pediatric Gastroenterology , Hepatology and Nutrition, Clinical Nutrition, American Journal of Respiratory and Critical Care Medicine, Journal of Cystic Fibrosis
Reviewer of MD Thesis
Guy Neeman Screening of Gluten Antibodies in Schizophrenia 2004
Oshrit CharashHemoptysis in CF Patients in Israel 2005
Organization of Conferences
European Cystic Fibrosis Diagnostic Network
2006 -Rotterdam
2007- Leuven
2008- Hannover
ESPGHAN Working Group on Cystic Fibrosis (at annual ESPGHAN meeting)
2006- Dresden
2007-Barcelona
Membership in Societies
1995 - American Gastroenterological Association
Israel Society of Gastroenterology
1996 - Israel Society of Pediatric Gastroenterology and Nutrition
1999 - European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
2000 - European Cystic Fibrosis Society
2002 – 2005 Secretary, CF Diagnostic Network, European Cystic Fibrosis Society.
2006 - Chairperson, CF Diagnostic Network, European Cystic Fibrosis Society
2004 - Co-chairperson, ESPGHAN Working Group on Cystic Fibrosis
2006 - Chairperson, ESPGHAN Working Group on Cystic Fibrosis
Awards
1992 - Outstanding Resident Award, Hebrew University, Jerusalem
1993 – 1995 Restracom Research Fellowship, Research Institute, The Hospital for Sick Children, Toronto, Canada
1993 – 1995 Canadian Cystic Fibrosis Foundation Research Fellowship
1994 - Tisdall Research Paper Award Finalist, The Hospital for Sick Children, Toronto, Canada
1995 - Tisdall Research Paper Award Winner, The Hospital for Sick Children, Toronto, Canada
1997 - Outstanding Teacher in Pediatrics, Hebrew University.
Hebrew University Faculty Prize for Pediatric Research
2000 - Young Investigator Award. World Congress of Pediatric Gastroenterology, Boston, USA
Research Grants
1. 1997-8 Hebrew University Research Grant. The Use of Nasal Potential Difference Measurements in Atypical Cystic Fibrosis. ($5000).
2. 1998-9 Hebrew University Research Grant ($10,000). Continuation of above (#18,19)
3. 1999-2000 North American Cystic Fibrosis Foundation Research Award Aminoglycoside antibiotics cause the restoration of CFTR function in cystic fibrosis patients carrying stop mutations. ($23,000/$40,000). Co-PI Prof. B Kerem (#17)
4. 1999 Israeli Ministry of Health Research Award Aminoglycoside antibiotics cause the restoration of CFTR function in cystic fibrosis patients carrying stop mutations. ($15,000). (#17,21)
5. 1999-2003 Israel Academy of Sciences Award Clinical Effect of Aminoglycoside antibiotics on cystic fibrosis patients carrying stop mutations ($37,000/$75,000). Co-PI Prof E Kerem (#17,21)
6. 2000 North American Cystic Fibrosis Foundation Research Award Double-blind study of topical gentamicin on CFTR function in cystic fibrosis patients carrying stop mutations. ($50,000) . (#21)
7. 2002 - Israeli Ministry of Health Research Award The effect of inhaled gentamicin on pulmonary function in cystic fibrosis patients carrying stop mutations. ( $7,500/15,000) Co-investigator Prof E Kerem
8. 2005 - Danone International Research Award Community Based Project to Prevent Obesity ($5000)
9. 2006 - North American Cystic Fibrosis Foundation Research Award Screening for Small Bowel Disease in Adult Cystic Fibrosis Patients ($50,000).
10. 2006 - PTC Therapeutics PTC124- proposed treatment for Cystic Fibrosis in patients carrying stop mutations Phase II ($40,000/$100,000). Co-investigators Prof E Kerem, Prof B Kerem.
11. 2007 - PTC Therapeutics PTC124- proposed treatment for Cystic Fibrosis in patients carrying stop mutations Phase IIB. ($100,000/$200,000). Co-investigator Prof E Kerem
12. 2007 - Altus Pharmaceuticals Phase III, randomized, double-blind, placebo-controlled sudy evaluating the efficacy and safety of Altu-3 (pancreatic enzyme) in CF patients. ($100,000)
Research Students/Teaching
Supervisor:Masters student.
1. Yasmin Yaakov (Prof A Ilani), Dept of Physiology, Hebrew University “Nasal Potential Difference Studies in CF” 1999-2004 (original paper #21)
2. Yael Shofan (Prof E Berry) Faculty of Agriculture, School of Nutrition, Hebrew University, 2004- 2007 Prevention of Obesity by Intervention Program in Israeli Schools
3. Dorit BenGad (Prof D Branski) Medical Psychology, Hebrew University, 2006 - The influence of chronic disease ( Inflammatory Bowel Disease) on quality of life and self esteem in children
Supervisor: MD Final project.
1. Fahed Hakim (Prof E Kerem), Hebrew University “Plasma Vitamin A and E Levels in CF” 2000-2002.
2. Gisella Sirota (Dr J Faber), Hebrew University “The efficacy of treatment of Helicobacter pylori infection in children”2000-2001.
3. Amir Weintraub (Prof E Kerem), Hebrew University “Pancreatic Function Status in Pancreatic Sufficient CF Patients” 2002-2004
4- Ranit Yaron, Hebrew University: Nasal Potential Difference Measurements – Patients Follow-Up” 2003-2005
Supervisor: 6 month Basic Science Rotation
1. Shmuel Benenson MD. (Internal Medicine) Co-supervisor (Dr. Y Schlesinger), Hebrew University "PCR Detection of Helicobacter pylori strains in Israeli Children” 2000-1. (#20)
2. Lena Rachman MD. (Pediatrics) Co-supervisor (Dr J Faber) Hebrew University' "Epidemiology of Helicobacter pylori in Jerusalem Schoolchildren." 1999.
3. Gidon Stern MBBS (Pediatrics) Hebrew University. “Intestinal current measurement – a new diagnostic test for cystic fibrosis. 2005.
4. Michael Cohen MD (Pediatrics) Hebrew University. “PTC124 – Proposed treatment for CF patients carrying stop mutations . 2006.
5. Muhanad Dana MD (Pediatrics) Hebrew University. "The Effect of PTC 124 on the cytokine profile of patients with Cystic Fibrosis. 2007”
6- Yishai Ben Ori MD (Pediatrics) Hebrew University. Capsule Endoscopy in Cystic Fibrosis .2007
Student and Postgraduate Teaching
1995 - present Didactic and bedside teaching to medical students, years 4 and 6
2000-2003 Teaching coordinator for 4th year Pediatrics students of Hebrew University (Shaare Zedek). Examiner in Pediatrics (6th year and part 2 Pediatrics)
2006 - Examiner in Pediatric Gastroenterology Specialization Kupat Cholim Health Fund
1997-present Lectures in Pediatric Gastroenterology to Pediatricians. (Director Dr R Litt)
Post-Doctoral Visitor
2006 - Prof S Werlin Pediatric Gastroenterology, Milwaukee, Wisconsin. Project: Capsule Endoscopy in Cystic Fibrosis -
Courses In Hebrew University
1999 - present Lectures in Pediatrics in Introductory Course to Clinical Medicine
1995 - present Pediatrics 4th year and 6th year
Articles Submitted
1. Hartman C, Berkowitz D, Weiss B, Shaoul R, Levine A, Eshach Adiv O, Shapira R, Fradkin A, Wilschanski M, Tamir A, Shamir R: Nutritional Supplementation with polymeric Diet Enriched with transforming growth factor β2 (TGF-β2) for children with Crohn's disease, the Israeli experience (submitted to Israel Medical Association Journal)
2. Elyashar-Earon H, Armony S,, Sciaki-Tamir Y, Kerem E, Wilschanski M Prolonged TPN during pregnancy in a Cystic Fibrosis patient with chronic pancreatitis. (submitted to Nutrition).
3. PTC124 Treatment of Cystic Fibrosis Due to Nonsense Mutations . E Kerem S Hirawat, B Kerem, S Armoni, Y Yaacov, H Blau, J Rivlin, M Aviram, D Shoseyov, M.Cohen, VJ Northcutt, GL Elfring, LL Miller M Wilschanski (to be submitted to Lancet)
Case Reports
1. Wilschanski M, PI Faber J, C Itai T, C Leifer M, C Abrahmov A. C 1987. Rheumatic Fever in a Child Aged Two Years M. Isr J Med Sci 23 (11), 1152-3; 0.456;62/110;0. 2;2
2. Wilschanski, PI Faber J C, Abramov A, C Isacsohn M, C Ehrlichman M. C 1989. Neonatal Septicaemia Caused by Group A Beta-Hemolytic Streptococcus. Pediatr Inf Dis J 8: 536-7; (3.047) Pediatrics 5/73; Infectious Diseases 11/43;6;6.
3. Wilschanski M, PI Abramov A, C Weintraub M, C Ferber B, C Glaser J, C Kaplan M. C 1992. Neonatal Pericarditis as a Presenting Manifestation of Chronic Granulomatous Disease. Acta Paed. 81:849-850; (1.582); 16/69; 1;1.
4. Wilschanski M, PI van der Hoeven E, C Phillips J, C Shuckett B, C Durie P. PI 1994. Shwachman-Diamond Syndrome Presenting as Hepatosplenomegaly. J Pediatr Gastr Nutr. 19:111-113;. (2.077) Pediatrics 10/73; Gastroenterology & Hepatology 20/46; 7;6
5. Bar Meir M, C Hadas-Halperin I, C Fisher D, C Rosenmann E, C Brautbar C, C Branski D, C Faber J, C Wilschanski M. PI2000. Neonatal Sclerosing cholangitis associated with autoimmune phenomena. J Pediatr Gastro Nutr 30:332-4; (2.077). Pediatrics 10/73; Gastroenterology & Hepatology 20/46; 2;2.
6. Virgilis, C E Kerem, C J Faber, C E Picard, C S Goldberg, C M Wilschanski PI 2002. Cystic fibrosis, pregnancy and acute pancreatitis. J Pediat Gastro Nutri 36:486-9. (2.077): Pediatrics 10/73; Gastroenterology & Hepatology 20/46;0.
Letters to Editor
1. Wilschanski M, Kaplan M. 1988. Phenobarbitone Increases Aminophylline Requirement in Premature Infants. Am. J. Dis. Child.142(2) 122-3; (1.530). 0
2. Wilschanski M, Schimmel M, Eidelman A. 1989. A Case of Neonatal Listeriosis in Israel -- Epidemiological Implications. Israel Medical Journal Harefuah (Hebrew) 116:129(2). 0
3. Wilschanski M. Schimmel S. 1991.Dangers of Interosseus Infusion. Israel Medical Journal Harefuah (Hebrew). 120 (11) 698-9. 0
4. Jarvi K, Zielenski J, Wilschanski M, Durie P, Buckspan M, Tullis E, Markievicz D, Tsui LC. 1995. Cystic Fibrosis Transmembrane Conductance Regulator and Obstructive Azoospermia. Lancet, 345:1578, (23.407); 2/105; 76;76
5. Wilschanski M, Corey M, Durie P, Tullis E, Bain J, Asch M, Ginzburg B, Jarvi K, Buckspan M, Hartwick W. 1996. Diversity of reproductive tract abnormalities in men with cystic fibrosis. JAMA. 276(8):607-8; (23.332); 3/105, 10;10
6. Wilschanski M, Faber J, Goldberg M, Branski D. 1999. Rectal biopsy in the investigation of constipation. Arch Dis. Child. 81:189; (1.787),16/73. 1;1
Invited Lectures (international)
1. July 1993 Update on Paediatric Crohn's Disease. Grand Rounds, The Hospital for Sick Children, Toronto, Canada
2. May 1994 Nutrition in Cystic Fibrosis. French CF Society, Monaco, France
3. May 1998 New Tests in Cystic Fibrosis. CF Symposium Co- Organizer - NASPGAN/ESPGHAN Conference, Toulouse, France
4. October 1998 Potential Difference Measurements in CF – Diagnosis and Treatment Monitoring. Hospital for Sick Children, Toronto, Canada.
5. June 2000 Electrophysiological Tests for the Diagnosis of CF. CF World Congress Stockholm, Sweden
6. Nov. 2000 Diagnosis and novel treatment strategies in CF. Department of Pediatric Gastroenterology, St. Bartholomews Hospital, London.
7. Oct. 2002 Pharmacogenetic Therapy of CF. Hospital for Sick Children, Toronto, Canada
8. August 2004 Aminoglycocide Treatment of Electrophysiological Abnormalities in cystic fibrosis. University of Paris, France
9. May 2005 AGA Symposium at Digestive Diseases Week. Novel Approaches to the Treatment of Cystic Fibrosis, Chicago, USA
10. June 2005 Early Detection of Liver Disease in Cystic Fibrosis. European Cystic Fibrosis Conference, Crete, Greece
11. April 2006 The Use of Nasal Potential Difference Measurements as a Marker of Treatment in CF. European CF Research Conference, Corveiro, Portugal
12. May 2006 Novel Approaches to the investigation and treatment of CF. GI Academic Rounds, British Columbia Children Hospital, Vancouver, Canada
13. June 2006 Chronic Liver Disease in CF. European Cystic Fibrosis Conference, Copenhagen, Denmark
14. Feb 2007 Nasal Potential Difference and Intestinal Current Measurement, Leuven, Belgium
15. May 2007 Novel Treatments for CF, European Society for Pediatric Gastroenterology, Hepatology and Nutrition, Barcelona, Spain
16. June 2007 Gastrointestinal Motility in CF, European CF Conference, Anatalya, Turkey
17. June 2007 Nasal Potential Difference- the ideal solution for diagnosis. European CF Conference, Anatalya, Turkey
18. January 2008 New aspects of CF Diagnosis. Swedish CF Conference, Stockholm, Sweden
Presentations
1. Wilschanski M, Kaplan M. Phenobarbitone Increases Aminophylline Requirement in Premature Infants. Presented at Israel Neonatology Society 1987. (oral)
2. Schimmel M, Wilschanski M, Rudensky B, Eidelman A. Respiratory Syncitial Virus -- How to Treat in the NICU. Presented at the International Workshop of the Israel Society of Paediatric Pulmonology 1987.(oral)
3. Wilschanski M, Schimmel M, Goren A, Isacsohn M. Prospective Study of Respiratory Syncitial Virus in Aetiology of Lower Respiratory Tract Infection in Infants and Children using a Rapid Detection Method in Two Epidemic Seasons 1986/7 and 1987/8. Presented at the Conference of the Israel Paediatric Association 1988.(oral)
4. Wilschanski M, Schimmel M, Isacsohn M, Eidelman A. A Case of Human Listeriosis in Israel - Does this Reflect a Change in the Epidemiology of Animal Listeriosis? Abstract no. 20. Conference of the Israel Paediatric Association 1988.(oral)
5. Goren A, Wilschanski M, Faber J, Alpeleg O, Steinberg A. Muscle Paralysis as a Life-Saving Treatment for Lactic Acidosis Secondary to a Metabolic Muscle Disease. Abstract no. 29. Conference of the Israel Paediatric Association, 1988.(oral)
6. Wilschanski M, Abrahamov A, Faber J, Schlesinger Y, Isacsohn M, Schechter A. Yersinia Enterocolitica -- A Forgotten Cause of Reactive Arthritis in Children. Presented at the Conference of the Israel Paediatric Association, 1988.(oral)
7. Wilschanski M, Hirsh H, Algur N, Drukker A. Congenital Nephrotic Syndrome - A Presentation of Four Cases and their Thyroid Function Studies. Presented at the Conference of the Israel Paediatric Association, 1990.(oral)
8. Schimmel M, Isaacsohn M, Rudensky B, Wilschanski M, Shag Y, Eidelman A. Unusual Presentation of Viral Disease in Early Infancy. Presented at IX Annual Meeting of European Society of Paediatric Infectious Diseases (ESPID), Barcelona, Spain, 1991(oral)
9. Bain J, Asch M, Margolis M, Ginzburg B, Buckspan M, Tullis E, Wilschanski M, Durie P. Scrotal Abnormalities in Men with Cystic Fibrosis. Presented at The Canadian Fertility and Andrology Society Meeting, 1994.(oral)
10. Chait P, Wilschanski M, Roberts E, Connolly B. Radiology of Primary Sclerosing Cholangitis (PSC) in Children. Presented at The Annual Meeting of the Radiology Society of North America, 1994. (oral)
11. Ginzburg BM, Buckspan MB, Bain J, Margolis M, Asch MR, Jarvi K, Tullis DE, Wilschanski M, Durie PR. Transrectal and Scrotal Ultrasound Abnormalities in Cystic Fibrosis. Annual Meeting of American Urological Association, Las Vegas, Nevada, 1995. (oral)
12. Wilschanski M, Bar-Meir M, Hadass-Halperin I, Faber J. Neonatal Sclerosing Cholangitis associated with autoimmune phenomena. Israel Society for Liver Disease 1996. (oral)
13. Wilschanski M, Fisher D, Hadas-Halperin I, Faber J, Kerem E, Branski D. Routine ultrasonographic examination of the abdomen in CF. European CF Meeting, Davos, Switzerland, 1997.(poster)
14. Wilschanski M, Faber J, Benenson S, Rudensky B, Rabinowitz N, Schlesinger Y, Branski D, Halle D. Antiobiotic Resistance of Helicobacter pylori isolated from Israeli children. Israeli Gastroenterology Society, Eilat, Israel, 2000. (oral)
15. Rahman L, Wilschanski M, Stankievicz H, Faber J. Epidemiology of Helicobacter pylori in Israeli children. Israeli Pediatric Gastroenterology Society, 2001. (oral)
16. Sirota G, Wilschanski M, Faber J. Helicobacter pylori treatment and follow-up in children. Israel Society of Pediatric Gastroenterology and Nutrition, 2002 (oral)
17. Wilschanski M. Helicobacter pylori - genotype and phenotype. Israel Society of Pediatric Gastroenterology and Nutrition, 2002. (oral)
18. Wilschanski M. Pharmacogenetic Approach to Treatment of CF. Israel Society of Pediatric Pulmonology, 2002 (oral).
19. Bar-Meir M, Faber J, Halle D, Schlesinger Y, Stankievicz H, Rudensky B, Wilschanski M. Antibiotic Sensitivity and Treatment of Helicobacter pyloriin children. Israel Society of Pediatric Gastroenterology and Nutrition 2003. (oral).
20. Wilschanski M , Yaakov Y, Adler S, Broide E, Blau H, Bibi H, Arnon R, Klar A, Vaisman N, Kolker O, Yahav Y, Arad-Chohen N, Kerem E. Nasal Potential Difference Measurements in Recurrent Pancreatitis. European Cystic Fibrosis Conference , Birmingham UK, 2004 (oral)
21. Wilschanski M, Schlesinger Y, Rudensky B, Faber J , Ohnona F, Refael S, Freier S, Halle D. The Combination of Helicobacter pylori strain and TNF polymorphism of the host increases the risk of peptic ulcer disease in children . Digestive Disease Week ,New Orleans , USA 2004 (poster)
22. Wilschanski M, Bar Meir M, Rudensky B, Schlesinger Y, Rachman E, Benenson S, Sorota G, Stankiewic H, Halle D, Faber J. Treatment regimens for Helicobacter pylori infection in children-is in vitro susceptlibility testing helpful? Digestive Disease Week ,New Orleans , LA, USA 2004 (oral)
23 Elyashar-Earon H, Kerem E, Armoni S, Wilschanski M. Gastrostomy removal in CF-is it wise? European Cystic Fibrosis Conference, Crete Greece, 2004 (poster)
24. Yaakov, Y, Kerem E, Yahav Y, Blau H, Rivlin J, Bentur L, Picard E, Aviram M, Wilschanski M. Reproducibility of nasal potential difference measurements in CF. European Cystic Fibrosis Conference, Crete Greece, 2004 (poster)
25. Wilschanski M, Ben-Nun A, Bromiker R, Kaplan M, Caplan C, Hammerman C. Probiotics decrease the incidence and severity of necrotizing enterocolitis in preterm infants. Digestive Disease Week, Chicago Ill, USA, 2005 (oral)
26. Bergwerk A, Shapiro R, Reif S, Wilschanski M, Bujanover Y. Capsule endoscopy in a series of preschool age children with obscure gastrointestinal bleeding Digestive Disease Week, Chicago Ill, USA, 2005 (poster)
27. Wilschanski M, Ben-Nun A, Bromiker R, Kaplan M, Caplan C, Hammerman C. Probiotics decrease the incidence and severity of necrotizing enterocolitis in preterm neonates European Society of Pediatric Gastroenteroloogy and Nutrition Porto, Portugal 2005 (poster).
28. Elyashar-Earon H, Kerem E, Armoni S, Wilschanski M. Gastrostomy tube removal in CF-is it wise? European Cystic Fibrosis Conference, Crete, Greece, 2005 (poster)
29. Yaakov Y, Kerem E, Yahav Y, Blau H, Rivlin J, Bentur L, Picard E, Aviram A, Wilschanski M. Reproducibility of nasal potential difference measurements in CF. European Cystic Fibrosis Conference Crete, Greece, 2005. (poster)
30. Wilschanski M, I Bjarnason, S Adler, E Kerem, E Goldin, J Zimmerman, S Armoni, Y Yatzkan-Israelit, A Bergwerk First Capsule Endoscopy studies in Cystic Fibrosis: description of CF enteropathy. North American CF Conference Baltimore MD, USA 2005 (oral)
31 Wilschanski M, A Weintraub, H Blau, H Mussafi, E Picard, L Bentur, E Kerem. Exocrine pancreatic function evaluation in patients with Cystic Fibrosis and pancreatic sufficiency : a correlation study. European Cystic Fibrosis Conference , Copenhagen, Denmark, 2006 (poster)
32. Shoseyov D, Cohen B, Armoni S, Castiel Y, Wilschanski M, Kerem E. Omeprazole treatment of gastro-esophageal reflux in cystic fibrosis. How much is enough? European Cystic Fibrosis Conference, Copenhagen, Denmark 2006 (poster)
33. Elyashar-Earon H, Armoni S, Kerem E, Wilschanski M. Pancreatitis during pregnancy in CF the option of TPN. European Cystic Fibrosis Conference, Copenhagen Denmark 2006 (oral)
34. Intestinal Current Measurement as a new Diagnostic Procedure for CysticFibrosis in infants and young children. Wilschanski M, Yaakov Y , Stern G, Shoseyov D, Bentur L, Golsdberg S, Shachar E, Kerem E. European Societry of Pediatric Gastroenteroloy, Hepatology and Nutrition, Barcelona 2007 (poster).
35. PTC124 Activity in CF Patients Carrying Stop Mutations: Interim Results of a Phase 2 Study M Wilschanski, S Hirawat, S Armoni, Y Yaacov, H Blau, J Rivlin, M Aviram, D Shoseyov, M.Cohen, VJ Northcutt, GL Elfring, LL Miller E Kerem European Societry of Pediatric Gastroenterology, Hepatology and Nutrition, Barcelona 2007 (poster).
36. Kohen M, Kerem E, Wilschanski M. Celiac Disease and Cystic Fibrosis . North American Cystic Fibrosis Conference, Denver, Colorado, USA November 2006).
37 .Kerem E, Blau H, Rivlin J, Aviram M, Shoseyov D, Yaakov Y, Armoni S, Wilschanski M. PTC124 activity in Cystic Fibrosis patients carrying stop mutations: interim results of a phase 2 study. North American Cystic Fibrosis Conference Denver, Colorado, USA November 2006, oral).
38. Yaakov,Y, Stern G, Bentur L, Kerem E, Wilschanski M. The Use of Intestinal Current Measurement from Rectal Biopsy tissue in the diagnosis of Cystic Fibrosis. North American Cystic Fibrosis Conference Denver, Colorado, USA November 2006,( poster).
39. CFTR ion channel function testing in recurrent, acute pancreatitis. Israel Society of Gastroenterology, Eilat December 2006 (oral).
40. Upper Gastrointestinal Bleeding in Familial Dysautonomia Patients
C. Maayan, S. Ben- Harush Negari, M. Wilschanski, J. Lachter
N American Dysautonomia Conference, May 2007, (oral).
41. Genetic Modifiers of severe Liver Disease in Cystic Fibrosis: A Replication Study. Stonebraker, J. R. Friedman, K. J.; Ling, S. C.; Cipolli, M. ; Debray, D. ; Fernandez, A. ; Lacaille, F. ; Repetto, G. ; Rowland, M. ; Taylor, C. ; Wainwright, C. ; Wilschanski, M. ; Pace, R. G.; Wood, S. D.; Dorfman, R. ; Wright, F. R.; Drumm, M. L.; Zielenski, J. ; Lange, E. M.; Durie, P. R.; Knowles, M. R. North American Cystic Fibrosis Conference 2007, (poster)
Scientific Biography
After Fellowship in Pediatric Gastroenterology, I set up the Electrophysiology Laboratory, firstly in Shaare Zedek Medical Center and in the last 4 years in Hadassah Medical Center. This Laboratory carries out studies in ion transport, particularly sodium and chloride ions, both in vivo (nasal potential difference measurements - NPD) and, more recently, in vitro (intestinal current measurement).
Research carried out at the laboratory in this field has been published widely, including defining an abnormal NPD and examining patients with single-organ manifestations like recurrent pancreatitis, a proportion of whom may have abnormally functioning CFTR protein (#18,19,22,26,28, 30,35,36). I have collaborated with the Toronto group in use of NPD is used as a diagnostic aid for Cystic Fibrosis (#29). I am chairman of the European Cystic Fibrosis Diagnostic Network, an international group of researchers in the field.
This methodology may be used to assess electrophysiological improvement after treatments for CF that are applied topically or systemically. I am co-Principle Investigator on the studies using aminoglycoside treatments for nonsense-mediated CF mutations (#17,21,34) and more recently the systemic treatment PTC124 (abstracts #35,37 articles submitted #7).
On the clinical aspect, I chair the ESPGHAN CF working group which aims to research gastroenterological aspects of CF on a Europe-wide scale. We have submitted our first consensus for publication on the distal intestinal obstruction syndrome (submitted #6) and are working on other aspects, including liver disease and gastroesophageal reflux in CF .
I am the principle investigator of the study investigating capsule endoscopy in CF (abstract #30)and have recently published a review of disease in adults associated with mutations in the CFTR gene #32. I have published on gastroenterological aspects of CF #15,16,33,37.
In other aspects of Pediatric Gastroenterology, I have published on genotype/phenotype factors in Helicobacter pylori infection (#20,25,31) and was co-Principle Investigator on a study investigating the use of probiotics to prevent necrotizing enterocolitis in premature infants (#27).